within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF07_TenofovirDisoproxil;

model TenofovirDisoproxil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.25,
    Cl = 3.5e-06,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.09670000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 10.001999999999999);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>TenofovirDisoproxil</td></tr><tr><td>ATC code:</td><td>J05AF07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>96.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>12.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NRTI) used as an antiretroviral medication for the treatment and prevention of HIV-1 infection and chronic hepatitis B. It is approved and widely used today as part of combination therapy regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults following single oral dose of tenofovir disoproxil 300 mg.</p><h4>References</h4><ol><li><p>Eke, AC, et al., &amp; Capparelli, EV (2021). Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. <i>Antimicrobial agents and chemotherapy</i> 65(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02168-20\">10.1128/AAC.02168-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33318014/\">https://pubmed.ncbi.nlm.nih.gov/33318014</a></p></li><li><p>Burns, RN, et al., &amp; Chaturvedula, A (2015). Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. <i>Journal of clinical pharmacology</i> 55(6) 629–638. DOI:<a href=\"https://doi.org/10.1002/jcph.461\">10.1002/jcph.461</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25581815/\">https://pubmed.ncbi.nlm.nih.gov/25581815</a></p></li><li><p>Kearney, BP, et al., &amp; Shah, J (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. <i>Clinical pharmacokinetics</i> 43(9) 595–612. DOI:<a href=\"https://doi.org/10.2165/00003088-200443090-00003\">10.2165/00003088-200443090-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15217303/\">https://pubmed.ncbi.nlm.nih.gov/15217303</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AF07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end TenofovirDisoproxil;
